目的: 了解系统性硬化症(systemic sclerosis，SSc)患者COVID-19疫苗接种及新型冠状(简称新冠)病毒感染情况。方法: 选取2016年1月至2023年3月于北京大学人民医院风湿免疫科住院，明确诊断为SSc的患者，通过住院病历检索和电话随访的形式，收集患者的临床特征、COVID-19疫苗接种及新冠病毒感染情况。结果: 236例SSc患者中有99例接受了电话随访及问卷调查，其中局限型SSc 41例、弥漫型SSc 28例、重叠综合征30例；患者接受了糖皮质激素(57.58%)、免疫抑制剂(56.57%)、生物制剂(7.07%)和小分子靶向药(6.06%)治疗。共49例患者接种过COVID-19疫苗，2022年11月至2023年3月期间共81例患者感染新冠病毒，接种三针及以上疫苗患者的感染率(19/29，65.5%)较未接种患者(45/50，90.0%)明显降低(P=0.007)。14例患者因新冠病毒感染住院治疗，26例患者感染后SSc症状有所加重，包括雷诺现象(Raynaud phenomenon)、皮肤病变、指端溃疡、肺动脉高压和肺间质病变等。与健康同居者相比较，SSc患者新冠病毒感染后发热(36.71%)、乏力(35.44%)等症状更严重。多因素回归分析显示，皮下钙质沉积(OR=7.713，95%CI：1.142~45.051)和抗着丝点抗体阳性(OR=9.210，95%CI：1.211~70.028)是SSc患者因新冠病毒感染入院治疗的独立危险因素。结论: 对于SSc患者，接种COVID-19疫苗对预防新冠病毒感染有效且安全；SSc患者新冠病毒感染后原发病加重，且感染症状也较无基础病人群加重。预防和早期合理治疗新冠病毒感染，对SSc患者具有重要意义。

Objective: To comprehensively understand the COVID-19 vaccination and infection status among patients with systemic sclerosis (SSc). Methods: We conducted a retrospective analysis of patients diagnosed with SSc who were hospitalized in the Rheumatology and Immunology Department of Peking University People' s Hospital from January 2016 to March 2023. We collected detailed clinical cha-racteristics, vaccination status, and infection details through a systematic review of medical records and telephone follow-ups with the SSc patients. Results: Out of 236 identified patients, 99 SSc patients participated in the follow-up. This cohort included 41 patients with limited SSc, 28 with diffuse SSc, and 30 with SSc overlap syndromes. Treatments varied, with glucocorticoids administered to 57.58% of patients, immunosuppressants to 56.57%, biologic agents to 7.07%, and small molecule targeted therapies to 6.06%. Notably, 49 patients had received the COVID-19 vaccine. Between November 2022 and March 2023, a total of 81 patients contracted COVID-19. The infection rate among those who received three doses or more (19/29, 65.5%) was significantly lower compared with unvaccinated patients (45/50, 90.0%, P=0.007). Fourteen of these patients required hospitalization due to COVID-19. Furthermore, 26 patients reported exacerbation of SSc symptoms post-infection, which included severe manifestations, such as Raynaud phenomenon, skin lesions, fingertip ulcers, pulmonary hypertension, and interstitial lung disease. Compared with healthy cohabitants, the SSc patients exhibited more severe symptoms following COVID-19, including fever (36.71%) and fatigue (35.44%). Multivariate regression analysis identified subcutaneous calcinosis (OR=7.713, 95%CI: 1.142-45.051) and positivity for anti-centromere antibodies (OR=9.210, 95%CI: 1.211-70.028) as independent risk factors for hospitalization due to COVID-19. Conclusion: Vaccination is both effective and safe in preventing COVID-19 among SSc patients. Additionally, it underscores that these patients experience exacerbation of their underlying disease and more severe COVID-19 symptoms compared with individuals without underlying conditions. Thus, proactive prevention, continuous monitoring, and early treatment of COVID-19 are of significant importance for the health and well-being of SSc patients. Timely interventions can help mitigate the impact of infections and improve overall patient outcomes.